EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The combination of Astragalus membranaceus and ligustrazine mitigates cerebral ischemia‐reperfusion injury via regulating NR2B‐ERK/CREB signaling

Xialing Tang, Shanshan Xie, Huajun Wang, Yingbin Li, Zhiyu Lai, Shuangxi Sun, Ruanhuan Pan, Yan Huang, Jun Cai iD

Brain and Behavior · 2023-02 · 13 (2)

DOI: 10.1002/brb3.2867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 31.12.2022. Verfasst von Xialing Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Brain Ischemia, Reperfusion Injury, Neuroprotective Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation and Strong University Project of Guangzhou University of Traditional Chinese Medicine, National Natural Science Foundation of China, Guangdong Provincial Key Laboratory of Chinese Medicine on Emergency in Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Cerebral ischemia‐reperfusion (I/R) injury is a major factor underlying the high mortality and morbidity rates in stroke patients. Our previous study found that the combination of Astragalus membranaceus extract and ligustrazine (Ast+Lig) treatment could protect brain tissues against inflammation in rats with thrombolytic cerebral ischemia. Activation of N‐methyl‐D‐aspartate receptors (NMDAR) is implicated in brain damage induced by cerebral I/R injury.

Methods

We used in vivo and in vitro models of cerebral I/R injury for middle cerebral artery occlusion/reperfusion in mice and oxygen‐glucose deprivation/reoxygenation in primary rat cerebral cortical neurons to evaluate the protective effects of Ast+Lig on cerebral I/R injury, and whether the protective mechanism was related to the regulation of NMDAR‐ERK/CREB signaling.

Results

Treatment with Ast+Lig, or MK‐801 (an inhibitor of NMDAR) significantly ameliorated neurological deficits, decreased infarct volumes, suppressed neuronal damage and Ca 2+ influx, and maintained the mitochondrial membrane potential in vivo and in vitro following cerebral I/R injury based on 2,3,5‐triphenyl tetrazolium chloride staining, immunohistochemistry, and immunofluorescent staining. Furthermore, treatment with Ast+Lig evidently prevented the upregulation of NR2B, but not NR2A, in vivo and in vitro following cerebral I/R injury based on western blotting and reverse transcription‐quantitative PCR analyses. Moreover, treatment with Ast+Lig significantly increased the phosphorylation of ERK and CREB, as well as increasing their mRNA expression levels in vivo and in vitro following cerebral I/R injury.

Conclusions

The overall results thus suggest that the Ast+Lig combination conferred neuroprotective properties against cerebral I/R injury via regulation of the NR2B‐ERK/CREB signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain IschemiaReperfusion InjuryNeuroprotective AgentsRatsMiceAnimalsAstragalus propinquusSignal TransductionReceptors, N-Methyl-D-AspartateInfarction, Middle Cerebral ArteryPyrazines

Stichwörter der Autor:innen

Astragalus membranaceusN-methyl-D-aspartate receptorscerebral ischemia-reperfusion injuryligustrazinestroke

Substanzen

Receptors, N-Methyl-D-AspartateNeuroprotective AgentstetramethylpyrazinePyrazines

Autor:innen und Institutionen

  • The Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Diagnosis and Treatment Center of Encephalopathy, Hubei Provincial Hospital of Chinese Medicine, Wuhan, China.
  • Diagnosis and Treatment Center of Encephalopathy, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
  • Department of Neurosurgery, Hospital of Guangzhou University Mega Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.

ORCID-Profile: Jun Cai

Förderung

  • Innovation and Strong University Project of Guangzhou University of Traditional Chinese Medicine
  • National Natural Science Foundation of China
  • Guangdong Provincial Key Laboratory of Chinese Medicine on Emergency in Traditional Chinese Medicine
  • Guangdong Provincial Key Laboratory of Chinese Medicine on Prevention and Treatment of Refractory Chronic Diseases
  • Project of Administration of Traditional Chinese Medicine of Guangdong Province of China

Zitieren

APA

Tang, X., Xie, S., Wang, H., Li, Y., Lai, Z., Sun, S., Pan, R., Huang, Y., & Cai, J. (2023). The combination of Astragalus membranaceus and ligustrazine mitigates cerebral ischemia‐reperfusion injury via regulating NR2B‐ERK/CREB signaling. Brain and Behavior, 13(2). https://doi.org/10.1002/brb3.2867

Vancouver

Tang X, Xie S, Wang H, Li Y, Lai Z, Sun S, et al. The combination of Astragalus membranaceus and ligustrazine mitigates cerebral ischemia‐reperfusion injury via regulating NR2B‐ERK/CREB signaling. Brain and Behavior. 2023;13(2). doi:10.1002/brb3.2867

BibTeX
@article{Tang2023,
  author = {Tang, Xialing and Xie, Shanshan and Wang, Huajun and Li, Yingbin and Lai, Zhiyu and Sun, Shuangxi and Pan, Ruanhuan and Huang, Yan and Cai, Jun},
  title = {The combination of Astragalus membranaceus and ligustrazine mitigates cerebral ischemia‐reperfusion injury via regulating NR2B‐ERK/CREB signaling},
  journal = {Brain and Behavior},
  year = {2023},
  volume = {13},
  number = {2},
  doi = {10.1002/brb3.2867}
}
Kostenlos starten →